Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company: “This acquisition has the potential to accelerate the availability of important rare disease medicines to more patients worldwide. The FTC’s complaint impacts patients and…